Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/10/2014 > 198 patent applications in 143 patent subcategories.

20140194340 - Diagnosing, monitoring and treating inflammation: The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems.... Agent: The Brigham And Women's Hospital, Inc.

20140194341 - Silica compositions: Compositions are provided, the compositions comprising: a silica compound containing at least one nitrogen atom; and a carboxylated polymer containing at least one nitrogen atom. The compositions may be useful to control algal growth, including harmful algal blooms (HAB).... Agent: Battelle Memorial Institute

20140194343 - Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases: m

20140194342 - Peptide-based peroxidase inhibitors and methods of using same: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction... Agent:

20140194344 - Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity: The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.... Agent: Rutgers, The State University Of New Jersey

20140194345 - Novel depsipeptide and uses thereof: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.... Agent:

20140194346 - Pasteurellaceae vaccines: The present invention relates to an N-glycosylated protein for treating and/or preventing bacterial Pasteurellaceae infection in a mammal or bird, wherein the protein is a Pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated N-X-S/T consensus sequence. In addition, the present invention is directed to corresponding... Agent: Eth Zurich

20140194347 - Influenza inhibiting compositions and methods: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza... Agent: The Administrators Of The Tulane Educational Fund

20140194348 - Method of inhibiting papillomavirus proliferation and treating papillomavirus infection: Methods for inhibiting virus proliferation and treating an individual having a papillomavirus infection preventing viral infection are disclosed. The methods include the steps of providing a composition comprising a plurality of papillomavirus virus-like particles or capsomeres and contacting papillomavirus-infected tissue of an individual with the composition under conditions effective to... Agent: University Of Rochester

20140194349 - Hiv protease inhibiting compounds: t

20140194350 - Macrocyclic proline derived hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Enanta Pharmaceuticals, Inc.

20140194351 - Hemipteran-and coleopteran active toxin proteins from bacillus thuringiensis: A novel Bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of Lygus insects is significantly inhibited by providing the novel crystal protein in Lygus insect diet. Polynucleotides encoding the crystal protein, transgenic plants and microorganisms that contain the polynucleotides, isolated peptides derived from the crystal protein, and... Agent: Monsanto Technology LLC

20140194352 - Compositions and methods for treatment of metabolic disorders and diseases: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21... Agent: Ngm Biopharmaceuticals, Inc.

20140194353 - Compositions and methods for the treatment of nervous disorders associated with diabetes: Compositions and methods for treating neural dysfunction. A exemplary method comprises administering to a subject having a neuropathy, e.g., a cognitive dysfunction or Alzheimer's, a therapeutically effective amount of an insulin or insulin analog, wherein the insulin or insulin analog crosses the BBB and/or a compound that increases SREBP-2 expression... Agent: Joslin Diabetes Center, Inc.

20140194354 - Methods for treatment of nephrotic syndrome and related conditions: The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary... Agent:

20140194355 - Isolated nucleic acid molecules encoding variant activin receptor polypeptides: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and... Agent: Amgen Inc.

20140194356 - Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein: The present invention is related to a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5.... Agent: Sandoz Ag

20140194357 - Modified relaxin polypeptides and their uses: Modified relaxin polypeptides and their uses thereof are provided... Agent: Ambrx, Inc.

20140194359 - Interfering rna delivery system and uses thereof: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.... Agent: Alcon Research, Ltd.

20140194358 - Prominin-1 peptide fragments and uses thereof: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.... Agent: Children's Medical Center Corporation

20140194360 - Use of antithrombin in extracorporeal membrane oxygenation: In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.... Agent: Revo Biologics, Inc.

20140194361 - Vault agents for treating chronic kidney disease: The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.... Agent:

20140194362 - Macrocyclic cysteine protease inhibitors and compositions thereof: The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one... Agent: Canterprise Limited

20140194363 - Compression-resistant collagen-based artificial bone repair material: The present invention provides a compression-resistant collagen-based artificial bone repair material that could be used for bone defect repair at human load-bearing sites. Such material has a composition and structure of self-assembled nano-sized calcium phosphate salt and collagen molecules, thereby possessing a biomimetic mineralization structure similar to the natural bone.... Agent: Beijing Allgens Medical And Technology Co, Ltd

20140194364 - Biomarkers for painful intervertebral discs and methods of use thereof: The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc.... Agent: The Regents Of The University Of California

20140194365 - Use of endostatin peptides for the treatment of fibrosis: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20140194367 - Agrocybe aegerita lectin aal-2, and encoding gene thereof, preparation method therefor and application thereof: The isolated Agrocybe aegerita lectin AAL-2 is able to inhibit the growth of tumor cells by inducing apoptosis. In the animal study, the Agrocybe aegerita lectin AAL-2 has been showed to be capable for tumor therapy. Furthermore, the AAL-2 preferentially binds to the carbohydrate or glycoproteins with its N-Acetylglucosamine, which... Agent: Wuhan Alpha-omega Biology Technology Co., Ltd(cn)

20140194366 - Ovarian cancer stem cells and methods of isolation and uses thereof: The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation... Agent: The General Hospital Corporation

20140194368 - Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70): The invention is directed to methods of treating cancer by administration of heat shock protein 70 (Hsp70) to the subject suffering from cancer.... Agent: Beech Tree Labs, Inc.

20140194369 - Cyclic lactadherin peptide mimetics and their uses: Provided herein is a new class of cyclic lactadherin peptides (cLac) that mimic the natural phosphatidylserine (PS)-binding activity of the parent lactadherin protein. These cLacs are useful as small molecule indicators of early stage of apoptosis and of treatment efficacy evaluation.... Agent: Trustees Of Boston College

20140194370 - Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer: A chemoembolic agent is disclosed that includes an injectable, recombinantly synthesized silk-elastin like protein copolymer and one or more chemotherapeutic agents. Upon injection, the chemoembolic agent blocks the tumor vasculature, including the capillary bed, and may optionally release chemotherapeutic agents. The chemoembolic agent may be used to treat cancer, including... Agent:

20140194371 - Solid oxidized glutathione salt and method for producing same: A solid oxidized glutathione salt is produced by heating an oxidized glutathione at 30° C. or higher while the oxidized glutathione is brought into contact with an aqueous medium in the presence of a substance for providing a cation, to produce the salt of the oxidized glutathione and the cation... Agent: Kaneka Corporation

20140194373 - Cosmetic use of hesperidin or a derivative thereof in the prevention and/or treatment of body odour: The present invention relates to the cosmetic use, in particular the oral use, of at least an effective amount of hesperidin or a derivative thereof as a deodorant agent.... Agent:

20140194372 - Heart failure suppressing agent: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active... Agent: The University Of Tokyo

20140194374 - Anthelmintic formulations and treatments: A new method of controlling worm burden in ruminants by using two different injectable anthelmintics at or about the same time to increase the time between treatments and to rely on the animal's immune response. One of the anthelmintics is a long acting formulation capable of providing a sustained release... Agent: Virbac

20140194376 - Isoxazoline derivatives as insecticidal compounds: The present invention provides compounds of formula (I) wherein G1 is oxygen; R1 is hydrogen; R2 is group (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is —C(R4)R4—; R3 is hydrogen or methyl; each R4 is independently... Agent: Syngenta Participations Ag

20140194375 - Topical antibiotic composition for the prevention of lyme disease: The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.... Agent: Ixodes Ag

20140194377 - Salts of isophosphoramide mustard and analogs thereof: e

20140194489 - Compositions and methods for inhibiting expression of tmprss6 gene: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.... Agent: Alnylam Pharmaceuticals, Inc.

20140194493 - Compositions and methods for inhibiting expression of transthyretin: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.... Agent: Alnylam Pharmaceuitcals, Inc.

20140194492 - Methods for treating hypercholesterolemia: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an... Agent: Isis Pharmaceuticals, Inc.

20140194491 - Modulation of microrna-138 for the treatment of bone loss: There is provided nucleic acids (mir-138 Antimirs) for use in treating or preventing bone loss in a patient. Also there is provided a method for reducing the levels of endogenous mir-138 in a cell.... Agent: Syddansk Universitet

20140194488 - Modulation of radiation response using microrna: The present invention relates to a technology of enhancing sensitivity to radiotherapy using microRNA, more particularly to a radiosensitizer composition comprising at least one selected from the group consisting of microRNA-26b, microRNA-203 and microRNA-200c, an anticancer supplement, and a method for enhancing sensitivity to radiotherapy of cancer cells using the... Agent:

20140194490 - Sequence-specific inhibition of small rna function: The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway,... Agent:

20140194494 - Modified polynucleotides for treating protein deficiency: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.... Agent: Moderna Therapeutics, Inc.

20140194378 - Methods of preventing or treating diseases and conditions using complex carbohydrates: The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as... Agent: Dermal Research Laboratories, Inc.

20140194379 - Methods for the production of chitin nanofibers and uses thereof: Methods for the production chitin nanofibers and uses thereof. Furthermore, methods for the production of chitin nanofibers and the fabrication of chitin nanofiber structures and devices.... Agent: University Of Washington Through Its Center For Commercialization

20140194380 - Method of manufacturing composition comprising local anesthetic, heparinoid, and buffer: An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise either: (A) (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid... Agent:

20140194386 - Beta-lactamase inhibitors: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.... Agent:

20140194381 - Boronic acid derivatives and therapeutic uses thereof: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.... Agent: Rempex Pharmaceuticals, Inc.

20140194382 - Boronic acid derivatives and therapeutic uses thereof: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.... Agent:

20140194384 - Boronic acid derivatives and therapeutic uses thereof: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.... Agent:

20140194385 - Boronic acid derivatives and therapeutic uses thereof: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.... Agent:

20140194387 - Derivatives of 1-amino-2-cyclobutylethylboronic acid: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20140194383 - Monomers capable of dimerizing in an aqueous solution, and methods of using same: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer,... Agent: Purdue Research Foundation

20140194388 - Combination therapy of hsp90 inhibitory compounds with chk inhibitors: A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical... Agent: Synta Pharmaceuticals Corp.

20140194389 - Bisphosphonate compounds: Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.... Agent: Warner Chilcott Company, LLC

20140194390 - Pesticidal compositions: wherein each of R1a and R1b which are independent of each other, is halogen; each of R2 and R3 is halogen, alkyl, haloalkyl, alkoxy, haloalkoxy or cyano; A is alkyl substituted by Y; Y is C3-4 cycloalkyl which may be substituted by at least one substituent selected from the group... Agent: Ishihara Sangyo Kaisha, Ltd.

20140194391 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: Normoxys, Inc.

20140194392 - Drug screening method: A drug screening method is disclosed. The drug screening method includes steps of screening a compound library to obtain a first group of compounds capable of binding to a wild type target; screening the first group of compounds to obtain a second group of compounds capable of binding to a... Agent: National Chiao Tung University

20140194393 - Tetracycline compositions: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.... Agent: Rempex Pharmaceuticals, Inc.

20140194395 - Compositions and methods for treating centrally mediated nausea and vomiting: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.... Agent: Helsinn Healthcare S.a.

20140194397 - Multiple-component pharmaceutical formulations and methods for their use in treating neuropathology and neurodegeneration caused by traumatic injury: Novel two-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as... Agent:

20140194396 - Organic compounds: The present invention relates to PDEI inhibitory compounds of Formula I as described herein, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent: Intra-cellular Therapies, Inc.

20140194398 - Tanaproget compositions containing ethinyl estradiol: Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol.... Agent: Wyeth LLC

20140194394 - Two-component formulations, methods and procedures to prevent or reduce trauma-induced neuropathology and neurodegeneration: Novel two-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as gabapentin. The... Agent:

20140194399 - Use of pufas for treating skin inflammation: v

20140194400 - Nasal pharmaceutical formulation: The present invention relates to a nasel formulation comprising as its active ingredient an intranasal corticosteroid, and also to a method for prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis and rhinoconjunctivitis.... Agent: Meda Pharma Gmbh & Co., Kg

20140194401 - Methods for reducing cellular proliferation and treating certain diseases: Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such... Agent: Brigham Young University

20140194406 - Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors: The present invention relates to alkynyl substituted pyrimidinyl-pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak and/or Src family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these... Agent: Nerviano Medical Sciences S.r.l.

20140194404 - Amidopyrazole inhibitors of interleukin receptor-associated kinases: This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.... Agent:

20140194405 - Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities: i

20140194403 - Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds:

20140194402 - Pyruvate kinase activators for use in therapy: Described herein are methods for using compounds that activate pyruvate kinase.... Agent: Agios Pharmaceuticals, Inc

20140194408 - Heteroaryl pyridone and aza-pyridone compounds: Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using... Agent: Genentech, Inc.

20140194407 - Novel antiplatelet agent: t

20140194409 - Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia: The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime.... Agent: H. Lundbeck A/s

20140194410 - Thiolactams and uses thereof: e

20140194411 - Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases,... Agent: Abt Holding Company

20140194412 - Thioxothiazolidine derivative having ras function inhibitory effect: e

20140194413 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent: Roche Palo Alto LLC

20140194414 - Tetracyclic compounds: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment... Agent: Medivation Technologies, Inc.

20140194415 - Fatty acid synthase inhibitors: This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.... Agent: Glaxosmithkline Intellectual Property (no2) Limite

20140194416 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under... Agent: The Johns Hopkins University

20140194417 - Irak inhibitors and uses thereof: The present invention provides compounds, compositions thereof, and methods of using the same.... Agent: Nimbus Iris, Inc.

20140194418 - Bicyclic carboxamide inhibitors of kinases: Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1˜X5, R1˜R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.... Agent: Abbvie Inc.

20140194419 - Chromenone derivatives: or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the... Agent: Astrazeneca Ab

20140194420 - Azabenzimidazole derivative having ampk-activating activity:

20140194421 - Heterocyclic glutaminase inhibitors: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.... Agent: Calithera Biosciences, Inc.

20140194423 - Combination products: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.... Agent:

20140194422 - Piperazine derivatives, compositions, and uses related thereto: The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase.... Agent: Emory University

20140194425 - Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, Inc.

20140194424 - Spirolactam derivatives and uses of same: e

20140194426 - Dual-acting oxazole antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent: Theravance, Inc.

20140194427 - Deuterium substituted fumarate derivatives: or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative... Agent: Biogen Idec Ma Inc.

20140194428 - Combination treatments for bipolar disorders: The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment of bipolar disorders.... Agent: Elan Pharmaceuticals. Inc.

20140194429 - Compositions for treatment of cancer: Compounds that are specifically toxic to cancer stem cells are disclosed.... Agent:

20140194430 - Substituted aminoimidazopyridazines: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a... Agent: Bayer Intellectual Property Gmbh

20140194433 - Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8: The invention relates to novel modulators of the cold menthol receptor TRPM8, to a method for modulating the TRPM8 receptor using said modulators; to the use of the modulators for induction of cold sensation; and to objects and means produced using said modulators.... Agent: Basf Se

20140194432 - Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease: e

20140194431 - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease:

20140194434 - Novel substituted indolo 4,3 fg quinolines useful for treating migraine: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing... Agent: Map Pharmaceuticals, Inc.

20140194435 - Novel substituted indolo 4,3 fg quinolines useful for treating migraine: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing... Agent: Map Pharmaceuticals, Inc.

20140194436 - Heteroarylmethyl amides: wherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis... Agent: Hoffmann-la Roche Inc.

20140194437 - Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor: e

20140194438 - Compositions and methods for treating centrally mediated nausea and vomiting: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.... Agent: Helsinn Healthcare S.a.

20140194439 - Methods of targeted drug development: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited... Agent:

20140194441 - 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis),... Agent: Samumed, LLC

20140194440 - 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases: The present invention relates to novel 5,6-disubstituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the manufacture of a medicament.... Agent:

20140194442 - Anticancer therapy: The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein.... Agent: Boehringer Ingelheim International Gmbh

20140194444 - Aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent:

20140194443 - Pyrazolyl-based carboxamides i: The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.... Agent: Gr&#xfc Nenthal Gmbh

20140194445 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals: wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases... Agent: Sanofi

20140194446 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.

20140194447 - Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies: Compounds and their pharmaceutically acceptable salts for treatment of β-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.... Agent:

20140194448 - Transvaginal phosphodiesterase inhibitors for infertility treatment: The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. It also relates... Agent:

20140194449 - Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof: Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a... Agent: Ambit Biosciences Corp.

20140194451 - Cdc42 inhibitor and uses thereof: Compounds which inhibit the small G protein Rho GTPase cell division cycle protein Cdc42 are provided. Morphological analyses of filopodia, western blots of Ccd42 phosphorylation, and effects on cellular wound healing and on growth cone formation all demonstrate that the described compounds are able to inhibit all tested Cdc42-mediated processes.... Agent:

20140194453 - Multicomponent crystalline system of rosuvastatin calcium salt and vanillin: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.... Agent: Basf Se

20140194452 - Pyrazolyl-based carboxamides ii: The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.... Agent: Gr&#xfc Nenthal Gmbh

20140194450 - Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.... Agent: Allergan, Inc.

20140194454 - Combinations of trospium and salivary stimulants for the treatment of overactive bladder: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying... Agent: Theravida, Inc.

20140194456 - Abuse-resistant controlled-release opioid dosage form: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Agent: Purdue Pharma

20140194457 - Carboxamide bioisosteres of opiates: u

20140194455 - Oxidation-stabilized tamper-resistant dosage form:

20140194458 - Derivate, preparation method and use of 10-methoxycamptothecine: Provided is a 10-methoxycamptothecine derivate of formula (1), wherein R is selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl substituted C1-6 alkyl, phosphate substituted C1-6 alkyl, amino-substituted C1-6 alkyl, carboxyl substituted C1-6 alkyl, hydroxyl substituted C1-6 alkyl, and amide- substituted C1-6 alkyl; R1 is selected from hydrogen and t-butoxycarbonyl substituted... Agent: Northeast Forestry University

20140194459 - Method and composition for treating an alpha adrenoceptor-mediated condition: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.... Agent: Vanda Pharmaceuticals, Inc.

20140194460 - Treatment of endometriosis: A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis.... Agent: Ferring B.v.

20140194461 - Rapamycin formulations and methods of their use: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.... Agent: Santen Pharmaceutical Co., Ltd.

20140194462 - Alpha-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof: The present application is related to compounds represented by Formula I, which are novel allosteric modulators of α7nAChR. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nAChR in a mammal by administering an effective amount of a compound of Formula I.... Agent: Anvyl LLC

20140194463 - Compositions for treatment of cancer: Compounds that are specifically toxic to cancer stem cells are disclosed.... Agent:

20140194464 - Crenolanib for treating flt3 mutated proliferative disorders: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered... Agent:

20140194465 - Compositions for treatment of cancer: Compounds that are specifically toxic to cancer stem cells are disclosed.... Agent:

20140194466 - Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm): The invention relates to perhexiline, or a pharmaceutically acceptable salt or enantiomer thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt or... Agent: The University Of Birmingham

20140194467 - Plasma cell disorders: The invention relates to novel biological markers for plasma cell disorders, such as multiple myeloma, and in particular to the use of microRNAs as diagnostic and prognostic markers in assays for detecting such disorders. The invention also relates to methods of determining the efficacy of treating a plasma cell disorder... Agent: The University Of Sussex

20140194468 - Compounds that suppress cancer cells and exhibit antitumor activity: The present invention provides compounds S3I-201.1066 (Formula 1) and S3I-201.2096 (Formula 2) as selective Stat3 binding agents that block Stat3 association with cognate receptor pTyr motifs, Stat3 phosphorylation and nuclear translocation, Stat3 transcriptional function, and consequently induced Stat3-specific antitumor cell effects in vitro and antitumor response in vivo.... Agent: University Of Central Florida Research Foundation, Inc.

20140194470 - Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof: in which n is equal to 0, 1, 2, 3 or 4; m is equal to 0, 1 or 2; o is equal to 0 or 1; X represents a group —CH2, —CH(R′)—, —NH(R′)— or a heteroatom chosen from O and S, it being understood that R′ represents a group... Agent: Sanofi

20140194469 - Histone demethylase inhibitors: Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer... Agent: Quanticel Pharmaceuticals, Inc.

20140194471 - Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors: In one aspect, the invention relates to substituted 1-benzylindolin-2-one analog compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders... Agent: Vanderbilt University

20140194472 - Vitamin d receptor-coregulator inhibitors: Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin D receptor target gene, inhibiting interactions between the vitamin D receptor and at least one vitamin D receptor coactivator, for treating cancer in a subject, and for inhibiting angiogenesis in a subject.... Agent: Uwm Research Foundation, Inc.

20140194473 - Imidazole fungicides: s

20140194474 - Composition for treating atherosclerosis and a preparation method thereof: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not... Agent: Kaohsiung Medical University

20140194475 - Animal parasite-control method using insect growth regulators: Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator and a mobile insect growth regulator to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to... Agent: The Hartz Mountain Corporation

20140194476 - Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease: t

20140194477 - Kinase protein binding inhibitors: The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.... Agent: Roswell Park Cancer Institute

20140194479 - Compositions and methods for treating mood disorders: The present invention provides, inter alia, methods for enhancing the anti-depressant efficacy of a selective serotonin re-uptake inhibitor (SSRI) in a patient being treated for a mood disorder. These methods include administering to a patient in need thereof a therapeutically effective amount of an SSRI and a therapeutically effective amount... Agent:

20140194478 - Compositions for treatment of cancer: Compounds that are specifically toxic to cancer stem cells are disclosed.... Agent:

20140194480 - Methods for the control of termites and ants: The present invention provides a method for controlling termites comprising applying a liquid formulation comprising a compound of formula I to a location where termite control is needed or is expected to be needed, wherein the compound of formula (I) is wherein X is optionally substituted aryl, optionally substituted heterocyclyl,... Agent: Syngenta Participations Ag

20140194481 - Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, Inc.

20140194482 - Compositions and methods of treatment of inflammatory skin conditions using allantoin: Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers,... Agent:

20140194483 - Inhibitors for steroid response elements and rna polymerase ii and related methods: The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The present invention also relates to polyamides capable of modulating the activity of RNA polymerase II and p53. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated... Agent:

20140194484 - Method of treating cachexia and sarcopenia: The present invention relates to a method of treating a cachexia and/or sarcopenia with an oral dose of S-pindolol or a pharmaceutical formulation thereof and to an oral formulation for use in said method of treatment. The method and oral formulation comprise administering a total daily dose of 2.5 to... Agent:

20140194485 - Isotopologues of isoindole derivatives: Provided herein are isoindole derivatives, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.... Agent: Celgene Corporation

20140194486 - Therapeutic agents: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein... Agent: Cancer Research Technology Limited

20140194487 - Novel formulation of indomethacin: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way... Agent: Iceutica Pty Ltd.

20140194495 - Cytotoxin compounds and methods of isolation: The present invention concerns groups of compounds derived from tunicates of the Synoicum species, as well as to pharmaceutical compositions comprising these compounds, and uses thereof. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in... Agent: University Of South Florida

20140194496 - Methods and compositions for inhibiting integrins using tellurium-containing compounds: Methods and compositions for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are methods and compositions for treating a neoplastic... Agent: Biomas Ltd.

20140194497 - Composition and method for scalp and hair treatment: Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness,... Agent: R-tech Ueno, Ltd.

20140194498 - Polyisoprenylated tetracyclic xanthone with anticancer activity: A novel polyisoprenylated tetracyclic xanthone, named garciesculentone B, isolated from Garcinia esculenta Y. H. Li is disclosed in the present invention. This compound is shown to have significant cytotoxicity against various cancer cells. In addition, garciesculentone B is shown to have antimigration effect on various cancer cells such as human... Agent: Hong Kong Baptist University

20140194499 - Polyprenylated benzoylphloroglucinols with anticancer activity: Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones A and C, are disclosed in the present invention. Garciesculentones A and C exhibit cytotoxicity and/or antimigration effect against various cancer cell lines. The experimental results of the present invention suggest that Garciesculentones A and C are useful for developing into anticancer drugs.... Agent: Hong Kong Baptist University

20140194501 - Composition for eyelash growth: The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2α analogues.... Agent: Sk Chemicals Co., Ltd.

20140194502 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that... Agent: Aradigm Corporation

20140194503 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that... Agent: Aradigm Corporation

20140194504 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that... Agent: Aradigm Corporation

20140194500 - Methods for treating of sars: Provided is a method of treating SARS in mammals. The method includes administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of SARS diseases to suppress the activities... Agent:

20140194505 - Neuraminidase inhibitors: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.... Agent: Sinevir Therapeutics LLC

20140194506 - Use of potassium piperonyl pentadienoate for lowering blood lipid: The invention provides the use of potassium piperonyl pentadienoate for lowering blood lipid, including the use of the potassium piperonyl pentadienoate in the preparation of medicaments and health-care products for lowering serum total cholesterol, lowering low density lipoprotein cholesterol, lowering triglyceride as well as preventing the decrease of high density... Agent: Borijihan Medical Company Of Wuhan

20140194507 - Compositions for treatment of cancer: Compounds that are specifically toxic to cancer stem cells are disclosed.... Agent:

20140194508 - Synthesis, methods of using, and compositions of cycloalkylmethylamines: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related... Agent: Reviva Pharmaceuticals, Inc.

20140194509 - Hydroxybutyrate ester and medical use thereof: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free... Agent: Isis Innovation Limited

20140194510 - Dispersions of rasagiline citrate: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.... Agent: Teva Pharmaceutical Industries Ltd.

20140194512 - Compositions comprising docosapentaenoic acid and methods of use: Orally administrable composition comprising fatty acids comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). The compositions can be used for the treatment or prophylaxis of a variety of conditions, including liver-related conditions.... Agent: Matinas Biopharma, Inc.

20140194511 - Dietary formulations and methods for treatment of inflammation and other disorders: Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C20 or longer omega-3 fatty acid and about 0.05% to 1% by calories... Agent: Children's Medical Center Corporation

20140194513 - Fermented vegetable oil and composition including same: The present invention relates to a fermented vegetable oil, to a method for preparing the oil, and to a composition including the oil. More particularly, the present invention relates to a technique for providing a fermented vegetable oil having the effects of enhancing emulsion stability due to water retention ability,... Agent: Damy Chemical Co., Ltd.

20140194514 - Topical formulations: Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms... Agent: Taraxos Inc.

20140194515 - Use of a composition comprising an antacid, a mucolytic and a gelling agent in the treatment of cold: The present invention is directed to a medicine to alleviate and cure colds by reducing acid content and stimulation of increased mucus production due to the fact that active components of the substance consist of acid stanching components like proton pumps stanches, histamine-2-receptor-antagonists, mucus stimulating components as acetylcysteine and alginic... Agent:

20140194516 - Medicaments containing pantothenic acid: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.... Agent: Prototype Bioforum Ltd.

20140194517 - Treatment of graft-versus-host disease disorders using rar antagonists: The present specification provides RAR antagonist compounds, compositions comprising such RAR antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RAR antagonists to manufacture a medicament and use of such... Agent: The Regents Of The University Of Minnesota

20140194518 - Antiseptic compositions, methods and systems: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses... Agent: Aseptica, Inc.

20140194519 - Antiseptic compositions, methods and systems: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses... Agent: Aseptica, Inc.

20140194520 - Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal... Agent: United Therapeutics Corporation

20140194521 - Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis: A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also... Agent: Protistia Biotechnology Ab

20140194522 - Emulsion composition: m

20140194523 - Desensitizing drug products and methods of use: Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products are disclosed herein.... Agent: Absorption Pharmaceuticals, LLC

20140194524 - Methods for treating alzheimer's disease: Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.... Agent: Cognition Pharmaceuticals, LLC

20140194525 - Exo-s-mecamylamine formulation and use in treatment: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine... Agent: Targacept, Inc.

20140194526 - Stabilized compositions of volatile alkylating agents and methods of using thereof: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include... Agent: Actelion Pharmaceuticals Ltd.

20140194527 - Geranylgeranylacetone formulations and retinal delivery thereof: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.... Agent: Rohto Usa, Inc.

20140194528 - Usage of sodium houttuyfonate on inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis: The present invention relates to a synthetic compound and its therapeutic uses. More particularly, it relates to a compound, Sodium Houttuyfonate, that is an addition compound of sodium bisulfite and houttuynin, and its biological activity of inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis... Agent: Hong Kong Baptist University

20140194529 - Usage of natural compound for treating inflammation and cancer: This invention relates to the use of a compound from natural sources for therapeutic uses. More particularly, it relates to a compound, Garcimultiflorone E, naturally occurring in the plant of Garcinia esculenta Y. H. Li which has potent anti-inflammation and anti-cancer effect.... Agent: Hong Kong Baptist University

20140194530 - Usage of oblongifolin c, a natural compound from garcinia yunnanensis hu, on treating cancer as metastasis inhibitor and autophagic flux inhibitor: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition... Agent: Hong Kong Baptist University

20140194531 - Hydroxytyrosol benefits mitochondria: Hydroxytyrosol or olive juice containing hydroxytyrosol ca in can he used to maintain or increase mitochondria(biogenesis in cardiac muscle, skeletal muscles, and liver tissue.... Agent: DsmIPAssets B.v.

20140194532 - Organopolysiloxane elastomer modified with mono-/diglycerin derivative, and use therefor: d

20140194533 - Biocompatible and biodegradable elastomer: The present invention provides a biocompatible and biodegradable elastomer, comprising a hard segment and a soft segment. The hard segment is formed by reacting diisocyanate and a chain extender; and the soft segment is comprising a biodegradable oligomer diol, wherein the biodegradable oligomer diol is selected from the group consisting... Agent: National Taiwan University

20140194534 - Refreshing cream foundation in gel form: The present invention is directed to a cosmetic composition includes (a) at least one compound selected from a sugar silicone surfactant, a gelling agent, a polyamine and a hyperbranched polyol; and (b) at least one polar modified polymer.... Agent: L'oreal

20140194535 - Anhydrous emulsions containing polylysine and polar modified polymer: The present invention generally relates to anhydrous emulsions containing an oil-soluble polar modified polymer and polylysine.... Agent: L'oreal

20140194536 - Low-viscosity liquid crystal compound: wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group... Agent: Chemgenesis Incorporated

20140194537 - Method for producing dispersant additives: The present invention relates to a method for producing an additive composition which in particular contains specific urea urethanes. The additive composition is extremely suitable as a wetting agent and dispersant.... Agent: Byk-chemie Gmbh

  
07/03/2014 > 183 patent applications in 133 patent subcategories.

20140187470 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase... Agent:

20140187471 - Template-fixed peptidomimetics with antimicrobial activity: e

20140187472 - Template-fixed peptidomimetics with antimicrobial activity:

20140187473 - Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-beta superfamily members: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as... Agent: Stryker Corporation

20140187474 - Therapeutic use of mucin glycans: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.... Agent:

20140187475 - Lantibiotic compositions and methods for preventing or treating mastitis: A composition suitable for application to the skin comprising at least one lantibiotic, an acidic external phase aqueous solution, at least one pharmaceutically acceptable internal phase carrier material, and a combination thereof. A method for preventing or treating mastitis, comprising administering to a human in need of such treatment a... Agent:

20140187477 - Inhibitors of viral integrase and methods of use: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.... Agent: Integratech Proteomics, LLC

20140187476 - Peptide derivative fusion inhibitors of hiv infection: This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral... Agent: Baobab Pharmaceuticals Limited

20140187478 - Peptide toxin formulation: Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic... Agent: Vestaron Corporation

20140187479 - Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism: Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism.... Agent:

20140187480 - Metabolic imprinting effects of specifically designed lipid component: The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy... Agent: N.v. Nutricia

20140187482 - Insulin preparation: The present invention relates to an insulin preparation that contains a self-assembling peptide. More specifically, the present invention is an insulin preparation containing a self-assembling peptide of SEQ ID NO:1.... Agent: The Doshisha

20140187481 - Transdermal pharmaceutical delivery composition: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at... Agent:

20140187483 - Glp-1 and methods for treating diabetes: The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday”. Practice of the invention achieves... Agent: Zealand Pharma A/s

20140187484 - Na/k-atpase-derived peptide src inhibitors and ouabain antagonists and uses thereof: A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.... Agent: The University Of Toledo

20140187485 - Novel receptor nucleic acids and polypeptides: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.... Agent: Biogen Idec Ma Inc.

20140187486 - Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive... Agent: Stryker Corporation

20140187487 - Affinity-based controlled release system: Prolonged or extended release of bioactive protein is achieved using an affinity-based approach which exploits the specific binding of Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methylcellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. Controlled release of chondroitinase... Agent:

20140187488 - Methods for maintaining pegylation of polypeptides: Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.... Agent: Bristol-myers Squibb Company

20140187489 - Mucosal delivery of drugs: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the... Agent: Arisgen Sa

20140187490 - Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation... Agent: Mannkind Corporation

20140187491 - Relaxin fusion polypeptides and uses thereof: The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the... Agent: Bayer Intellectual Property Gmbh

20140187492 - Single component fibrin hemostat: ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive... Agent:

20140187493 - Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity: The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer.... Agent: Soricimed Biopharma Inc.

20140187494 - Inhibition of inflammation using antagonists of muc1: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling.... Agent: Dana-farber Cancer Institute, Inc.

20140187495 - Methods for treating glioblastoma: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.... Agent: University Of Massachusetts

20140187496 - Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss.... Agent:

20140187497 - Ocular drug delivery devices: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method... Agent: Aton Pharma, Inc.

20140187498 - Predicting and treating diabetic complications: Compositions and methods for diagnosing, predicting risk of, and/or treating diabetic retinopathy and/or diabetic nephropathy.... Agent:

20140187499 - Substituted anionic compounds consisting of a backbone made up of a discrete number of saccharide units: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1≦u≦8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic... Agent:

20140187500 - Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines: The present application provides, among other things, compounds, compositions and methods for treating various diseases including cancer.... Agent: Massachusetts Institute Of Technology

20140187501 - Targeted conjugates encapsulated in particles and formulations thereof: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making... Agent: Blend Therapeutics, Inc.

20140187502 - Peptide linkers for polypeptide compositions and methods for using same: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in... Agent: Shire Human Genetic Therapies, Inc.

20140187503 - Diagnostic method: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.... Agent: Hansa Medical Ab

20140187504 - Prevention and treatment of inflammatory conditions: The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene... Agent: Glycoreregimmune, Inc.

20140187505 - Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders: Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to... Agent:

20140187506 - Inhibitors of advanced glycation end products: s

20140187507 - Treatment of parkinsons disease with glycolipids: This invention provides compounds, compositions, and methods for treating Parkinson's disease. In particular, there is provided GM1 ganglioside analogs that are capable of penetrating the blood brain barrier and entering the cytoplasm of neurons. Endogenous GM1 interacts with the with GFRα1/RET, the GDNF receptor complex involved in GDNF signaling which... Agent:

20140187508 - Synergistic fungicidal compositions: A synergistic fungicidal mixture contains a fungicidally effective amount of a compound of Formula I and at least one fungicide selected from the group consisting of tricyclazole, azoxystrobin, carpropamid, probenazole, kasugamycin, and boscalid.... Agent: Dow Agroscience LLC

20140187602 - Anti-sense oligonucleotides targeted against exon 9 of il-23r alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23Rαgene. Exon 9 skipping of the IL23Rα gene ultimately causes specific induction of a novel soluble truncated IL-23Rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino... Agent: Medical Diagnostic Laboratories, LLC

20140187601 - Antisense oligonucleotide modulation of raf gene expression: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided.... Agent:

20140187610 - Connective tissue growth factor antisense oligonucleotides: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions... Agent: Fibrogen, Inc.

20140187608 - Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction: The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed “Mirta22,” that inhibits the formation of structures which create connections between neurons. It is further based, in part, on the discovery that inhibiting Mirta22... Agent:

20140187607 - Methods of modulating compliance of the trabecular meshwork: The present invention relates to method, system, and composition for modulating the compliance of the trabecular meshwork, which may provide treatment to glaucoma.... Agent: The Regents Of The University Of California

20140187603 - Microrna inhibitors comprising locked nucleotides: The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-208 family miRNAs, including miR-208a, miR-208b, and/or miR-499. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-208a, miR-208b, and miR-499. The invention further... Agent: Miragen Therapeutics

20140187611 - Mitochondrial ribosomal proteins as aging regulators: The present invention relates to methods of increasing lifespan, delaying aging, and/or preventing or treating an age-related disease or a mitochondrial disease in a subject, comprising inducing a nuclear-mitochondrial OXPHOS protein dyssynchrony, including inhibiting the mitochondrial translation machinery function, as well as methods for screening agents that are able to... Agent: Ecole Polytechnique Federale De Lausanne

20140187609 - Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer: Methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155 are described.... Agent: The Ohio State University

20140187605 - Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg): The invention relates to the field of endothelial barrier dysfunction, particular, the invention relates to new methods for the treatment of endothelial barrier dysfunction, such as inflammatory edema by inhibiting Abl-related gene (ARG).... Agent: Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Pati&#xcb Ntenzorg

20140187604 - Therapeutic and diagnostic target gene in acute myeloid leukemia: Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20140187606 - Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Frataxin (FXN), in particular, by targeting natural antisense polynucleotides of Frataxin (FXN). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression... Agent: Curna, Inc.

20140187614 - Amino lipids, their synthesis and uses thereof: The present invention provides new amino lipids and a convenient method for synthesising these compounds. These (cationic) amino lipids have good properties as transfection agents. The method is an economic versatile two step synthesis allowing the preparation of various amino lipids thus leading to the assembly of a combinatorial library... Agent: Incella Gmbh

20140187612 - Method of modulating integrin mediated cellular activity and agents useful for same: An isolated nucleic acid encodes a polypeptide for inhibiting growth of a cancer cell. The amino acid sequence defines a binding domain of a β integrin subunit for ERK2 MAP kinase, the binding domain comprising an intervening, centrally located amino acid linker sequence that links opposite terminal end amino acid... Agent: Inter-k Pty Limited

20140187613 - Methods and products for expression of micro rnas: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.... Agent: Whitehead Institute For Biomedical Research

20140187615 - Therapeutic polynucleotides, compositions, and methods: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally,... Agent: Regents Of The University Of Minnesota

20140187509 - Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction: The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) S-adenosylmethionine or a derivative or pharmaceutically acceptable salt thereof and (ii) N-acetylcysteine or a derivative or pharmaceutically acceptable salt thereof; (b) vitamin E or a... Agent: Scimar Ltd.

20140187510 - Molecular activators of the wnt/beta-catenin pathway: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in... Agent: University Of Washington Through Its Center For Center For Commercialization

20140187511 - Nucleoside phosphoramidate prodrugs: e

20140187513 - Method of improving skills with a composition comprising non-digestible saccharide: The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.... Agent: N.v. Nutricia

20140187512 - Use of lactulose in the treatment of autism: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are... Agent: Curemark LLC

20140187514 - Use of iron(iii) complex compounds: The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defense and/or brain performance.... Agent: Vifor (international) Ag

20140187515 - Method for reducing damage by harmful organisms in corn cultivation: Provided is a method for reducing damage by harmful organisms in corn cultivation. Damage by harmful organisms in corn cultivation can be reduced by carrying out the steps of: A) making a furrow in a cultivated land; B) seeding corn into the furrow formed in the foregoing step; C) applying... Agent: Sumitomo Chemical Company, Limited

20140187516 - Dosage regimen of an s1p receptor modulator: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.... Agent: Novartis Ag

20140187517 - Method for treating intestinal diseases presenting at least one inflammatory component: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.... Agent: Cosmo Technologies Limited

20140187518 - Anti-itch scalp treatment compositions and combinations: Provided herein are sulfate free and/or sodium chloride free scalp treatment compositions comprising corticosteroid, combinations containing these compositions, kits and methods, particularly for treating and/or preventing itchy scalp.... Agent:

20140187519 - Biomarkers for predicting major adverse events: Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140187521 - Amelioration of intestinal fibrosis and treatment of crohn's disease: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound.... Agent:

20140187520 - Stable injectable pharmaceutical composition of vitamin d receptor agonist and process for preparation thereof: The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a Vitamin D receptor agonist, particularly paricalcitol, and a process of preparation thereof.... Agent: Pharmathen S.a.

20140187522 - Use of 2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.... Agent: Wisconsin Alumni Research Foundation

20140187523 - Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: The Regents Of The University Of California

20140187524 - Treatment of depressive disorders: Pregn-4-en-20-yn-3β-one is useful in the treatment of depressive disorders by nasal administration.... Agent: Pherin Pharmaceuticals, Inc.

20140187525 - Method for treating uterine fibroids: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for... Agent: Laboratoire Hra-pharma

20140187526 - Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition: The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound having the structure of Formula I or II:... Agent: Pono Corporation

20140187527 - Macrocyclic compounds and metal complexes for bioimaging and biomedical applications: The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear... Agent: National Yang Ming University

20140187528 - Tazobactam arginine antibiotic compositions: This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions.... Agent:

20140187532 - 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics: i

20140187533 - Benzimidazole inhibitors of the sodium channel: The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety... Agent: Zalicus Pharmaceuticals Ltd.

20140187534 - Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof: e

20140187529 - Aminopyrazine compounds:

20140187531 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent: Abbvie Inc.

20140187530 - Aza spiro alkane derivatives as inhibitors of metalloproteases: s

20140187535 - Substituted benzimidazole-type piperidine compounds and uses thereof: and pharmaceutically acceptable salts or solvates thereof, e.g., a pharmaceutically acceptable salt or solvate, wherein R1, R2, R3, Qa, W, U, A, B, Z, a, and the dashed lines are as defined herein, compositions comprising an effective amount of a Substituted Benzimidazole-Type Piperidine Compound, and methods to treat or prevent... Agent: Purdue Pharma L.p.

20140187536 - Agents for preventing and treating disorders involving modulation of the ryanodine receptors: Methods for reducing toxicity or side effects caused by administration of a rycal compound for repairing ryanodine receptor channel leaks when treating a disorder in a subject caused by such leaks. These methods are based upon the selection for administration of those rycal compounds having properties including an EC50 value... Agent: The Trustees Of Columbia University In The City Of New York

20140187537 - Methods of predicting outcomes of chemotherapy treatments and alternative therapies: This disclosure relates to diagnostic and therapeutic methods and systems related thereto. In certain embodiments, the disclosure contemplates methods of improving chemotherapy treatments by administering chemotherapy agents, analyzing CHFR gene expression, methylation, or both, and determining an appropriate therapeutic strategy. Analysis of data herein revealed that reduced CHFR expression levels... Agent: Emory University

20140187538 - Lorcaserin hydrochloride: The present invention relates to amorphous lorcaserin hydrochloride; amorphous solid dispersion comprising lorcaserin hydrochloride and one or more pharmaceutically acceptable carries; processes for preparation thereof; pharmaceutical compositions comprising amorphous lorcaserin hydrochloride and one or more pharmaceutically acceptable carries.... Agent: Dr. Reddy's Laboratories Ltd.

20140187539 - Novel benzamides, production thereof, and use thereof as medicaments: e

20140187540 - Compounds and methods of use thereof for treating neurodegenerative disorders: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.... Agent: The Johns Hopkins University

20140187541 - Composition and method for controlling harmful arthropods: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising a carboxylic acid compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and... Agent:

20140187542 - Amino group-containing pyrrolidinone derivative: e

20140187543 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them:

20140187544 - Oxime-substituted-quinoxaline-type piperidine compounds and uses thereof: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R20, R21, Q, Y1, Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering... Agent: Purdue Pharma L.p.

20140187545 - Pyrazolopyrimidine derivatives as pi3 kinase inhibitors: PI3Kβ selective compounds having the structure... Agent: Glaxosmithkline LLC

20140187546 - Cystine diamide analogs for the prevention of cystine stone formation in cystinuria: 3

20140187547 - Azaindenoisoquinoline topoisomerase i inhibitors: The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.... Agent: Purdue Research Foundation

20140187548 - 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders: The present invention relates to substituted imidazopyrazine compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds... Agent: Bayer Intellectual Property Gmbh

20140187549 - Pyridonemorphinan analogs and biological activity on opioid receptors: and pharmaceutically acceptable salts and solvates thereof, wherein , R1a, R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as... Agent: Purdue Pharma L.p.

20140187551 - 7-azaindole derivatives suitable for treatment of cancers: Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.... Agent: Merck Patent Gmbh

20140187550 - Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions: m

20140187553 - Azole compounds as pim inhibitors: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein,... Agent: Amgem Inc.

20140187552 - Method of treatment of aggression: The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.... Agent: Supernus Pharmaceuticals, Inc.

20140187554 - Modulators of the nuclear hormone receptor ror: The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods... Agent: The Scripps Research Institute

20140187555 - Novel soft pde4 inhibitors: The present invention relates to new phosphodiesterase inhibitors, more specifically soft PDE4 inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new soft PDE4 inhibitors compositions, in particular pharmaceuticals, comprising such... Agent: Amakem Nv

20140187556 - Anti-amyloid compounds and methods: Anti-amyloid compounds are provided along with methods of use thereof.... Agent: Treventis Corporation

20140187557 - Benzocycloheptane and benzoxepine derivatives: t

20140187559 - Inhibitors of the fibroblast growth factor receptor: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.... Agent: Blueprint Medicines Corporation

20140187558 - Preparation of sitagliptin intermediates: The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.... Agent: Lek Pharmaceuticals D.d.

20140187560 - Bromocriptine formulations: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes.... Agent: Veroscience LLC

20140187561 - Salts of fenofibric acid and pharmaceutical formulations thereof: e

20140187562 - Preparation of crystalline forms of dihydropyrazolopyrimidinone: The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775.... Agent:

20140187563 - Combination therapy in treatment of oncological and fibrotic diseases: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.... Agent: Boehringer Ingelheim International Gmbh

20140187564 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20140187565 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20140187566 - Pharmaceutical combination of mek inhibitor and b-raf inhibitors: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the... Agent: Glaxosmithkline LLC

20140187567 - Agricultural or horticultural fungicide composition and method for controlling plant pathogen: A composition having a stable and high fungicidal effect against a cultivated crop infected by a plant pathogen is provided. An agricultural or horticultural fungicide composition containing, as active ingredients, (a) fluazinam or its salt and (b) a strobilurin compound or its salt is provided; in addition, a method for... Agent: Ishihara Sangyo Kaisha, Ltd.

20140187568 - Crystalline forms of bosentan salts and processes for their preparation: The present invention relates to crystalline forms of bosentan salts and processes for their preparation.... Agent: Ranbaxy Laboratories Limited

20140187569 - Crystalline forms of bosentan salts and processes for their preparation: The present invention relates to crystalline forms of bosentan salts and processes for their preparation.... Agent: Ranbaxy Laboratories Limited

20140187570 - Novel formulations of pyrimethanil, and their use in treatment of crops: Solutions and emulsions of pyrimethanil and essential oils, and their use in fungicidal treatment of crops.... Agent: Xeda International

20140187571 - 7,8-cyclicmorphinan analogs: and pharmaceutically acceptable salts and solvates thereof, wherein Cy, R1a-R3a, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.... Agent: Purdue Pharma L.p.

20140187572 - Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady... Agent: Purdue Pharma L.p.

20140187573 - Substituted morphinans and the use thereof: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic... Agent: Purdue Pharma L.p.

20140187574 - Use of rapamycin derivatives in vasculopathies and xenotransplantation: Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.... Agent:

20140187575 - Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are... Agent: Medicis Pharmaceutical Corporation

20140187576 - Salt of naphthyridine carboxylic acid derivative: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.... Agent:

20140187577 - Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of... Agent: Eisai R&d Management Co., Ltd.

20140187578 - Pharmaceutical topical compositions: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.... Agent: Ferrer Internacional, S.a.

20140187579 - Tip60 inhibitors: This invention is in the fields of immunology and autoimmunity. More particularly it concerns pharmaceutical compositions comprising compounds which are useful agents for inhibiting the functions of TIP60 and the use of such compounds in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel... Agent: The Trustees Of The University Of Pennsylvania

20140187580 - Spin traps and spin labels for the treatment of rectal hemorrhoids: Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the treatment of rectal hemorrhoids and rectal fissures.... Agent:

20140187581 - Heteroaryl compounds as 5-ht4 receptor ligands: t

20140187583 - Polymorph form of 4-methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid: The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II), and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.... Agent: Raqualia Pharma Inc.

20140187582 - Solid dispersions of amorphous paroxetine mesylate: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA),... Agent:

20140187584 - Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnfalpha levels: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal.... Agent: Celgene Corporation

20140187585 - 5-ht2b receptor antagonists: The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT2B receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.... Agent: Janssen Pharmaceutica, Nv

20140187586 - Pyridylphenyl compounds for inflammation and immune-related uses: e

20140187589 - Fungicidal compositions for controlling leaf spots in sugar beets: A new method for the control and prevention of sugar beet leaf spot caused by Cercospora beticola (CERCBE) in a sugar beet plant has been discovered. The method involves applying effective amounts of Formula I to sugar beets.... Agent: Dow Agrosciences LLC

20140187588 - Macrocyclic picolinamides as fungicides: The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides.... Agent:

20140187590 - Synergistic fungicidal compositions: A synergistic fungicidal mixture contains a fungicidally effective amount of a compound of Formula I, (3S,6S,7R,8R)-8-benzyl-3-(3-((isobutyryloxy)methoxy)-4-methoxypicolinamido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate, and at least one triazole fungicide wherein Formula I is... Agent: Dow Agrosciences LLC

20140187587 - Synergistic fungicidal mixtures for fungal control in cereals: A fungicidal composition containing a fungicidally effective amount of (a) the compound of Formula I, (3S,6S,7R,8R)-8-benzyl-3-(3-((isobutyryloxy)methoxy)-4-methoxypicolinamido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate, and (b) fluxapyroxad, provides synergistic control of selected fungi.... Agent:

20140187591 - Solid form and method for preparing the same: The disclosure provides a solid form and a method for preparing the same. The solid form consists essentially of a biodegradable copolymer and an amide-containing compound. The biodegradable copolymer is semi-crystalline due to the dipole-dipole interaction between the biodegradable copolymer and the urea. The method for preparing the above solid... Agent: Industrial Technology Research Institute

20140187592 - Nitrogen-containing aromatic heterocyclyl compound: The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl,... Agent: Daiichi Sankyo Company, Limited

20140187593 - Diagnostic test and treatment for a neurological disorder: Methods and compositions relating to diagnosing and treating a VMAT-2 deficiency disease are described. Provided are methods for screening for, diagnosing or detecting a risk of developing a VMAT-2 deficiency disease comprising detecting the presence of a VMAT-2 variant in a sample of a subject, wherein the presence of the... Agent:

20140187594 - Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases: Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic... Agent: Orchid Chemicals And Pharmaceuticals Ltd

20140187595 - Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1): The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator <eq.metformin or troglizazone>.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20140187596 - Fatty acid amide hydrolase inhihibitors for treating pain: The present invention provides a method of treating a patient suffering from pain or other FAAH mediated conditions by administering a fatty acid amide inhibiting amount of a compound represented by the formula: wherein R1 is H; R2 is a radical selected from the group consisting of H, hydrocarbyl and... Agent: Allergan, Inc.

20140187597 - Pharmaceutical compositions for the treatment of movement disorders: A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.... Agent: Sarah Herzog Memorial Hospital Ezrath Nashim Association

20140187598 - Novel solid forms of bendamustine hydrochloride: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.... Agent: Cephalon, Inc.

20140187599 - Methods for treating diseases using isoindoline compounds: Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, cyclopropyl {2-[(15)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination... Agent: Celgene Corporation

20140187600 - Use of metabotropic glutamate receptors: The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.... Agent:

20140187616 - Calcium channel proteins and uses thereof: Described herein are compositions and uses thereof related to Ca2+ release-activated Ca2+ (CRAC) channel activity. Also described herein CRAC channel modulators for treating diseases or conditions that would benefit from inhibition of SOC channel activity.... Agent:

20140187617 - Dual mechanism inhibitors for the treatment of disease: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One... Agent: Aerie Pharmaceuticals, Inc.

20140187618 - Compositions, methods and kits using for inducing or enhancing neurogenesis in cells and tissue: Compositions, methods, and kits including extracts containing physalins and pure physalins are provided for inducing neurogenesis in cells and tissues. The extracts for example are obtained from natural sources such as a plant, for example Physalis angulata. The extracts and purified physalins increase proliferation of neural stem cells, differentiation of... Agent: Biocrescentia, LLC

20140187619 - Treatments for diabetes mellitus and obesity: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise the step of administering an active agent directly to the small intestine in the subject. In particular, the active agent may be administered directly to the duodenum in the subject. The active agents useful... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140187620 - Composition comprising coumestrol or a bean extract containing coumestrol: The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.... Agent: Amorepacific Corporation

20140187621 - Composition comprising coumestrol or a bean extract containing coumestrol: The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.... Agent: Amorepacific Corporation

20140187622 - Composition comprising coumestrol or a bean extract containing coumestrol: The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.... Agent: Amorepacific Corporation

20140187623 - Escalating dosing regimen for effecting weight loss and treating obesity: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate... Agent:

20140187624 - Method of managing chemotherapy induced alopecia or cachexia or both: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.... Agent: Indus Biotech Private Limited

20140187625 - Rodenticidal compound, composition including same and use for combating rodent pests: A novel compound obtained from molecules of the coumarin family, which exhibits rodenticidal activity. Also, compositions which incorporate such compounds and the use thereof for combating rodent pests.... Agent: Liphatech

20140187626 - Oxanorbornadiene derivatives and their anticancer activities: The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects.... Agent: Hong Kong Baptist University

20140187627 - Uses of c15-substituted andrographolide derivatives in the preparation of anti-hepatitis b virus medicament: Disclosed is a use of C15-substituted andrographolide derivatives in preparation of anti-hepatitis B virus medicaments. In the present invention, the HepG2.2.15 cells are used to measure the amount of the hepatitis B virus surface antigen (HBsAg) secretion in the supernatant of the culture; the duck hepatitis B virus (DHBV) is... Agent: Zhengzhou University

20140187628 - Palatable suspending vehicle for pharmaceutical ingredients: The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least... Agent: Fagron, Inc

20140187629 - Use of bethanechol for treatment of xerostomia: A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed.... Agent:

20140187630 - Novel compound and medical use thereof: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood... Agent: Ono Pharmaceuticals Co., Ltd.

20140187632 - Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.... Agent: Enzymotec Ltd.

20140187631 - Methods for treating brain injury: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).... Agent:

20140187633 - Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis: In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharmaceuticals Ireland Limited

20140187634 - Cure for edema of the foot and ankle: The inventive subject matter relates to a method for treating Edema of the Foot and Ankle Edema is a medical condition characterized by swelling and discoloration caused by excess fluid trapped in the body tissues. Administration of Extra Virgin Olive Oil composition provides therapeutic results when applied to the affected... Agent:

20140187635 - Diclofenac compositions: The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries,... Agent: Themis Medicare Limited

20140187636 - Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as,... Agent: Allergan, Inc.

20140187637 - Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof: The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such... Agent: Allergan, Inc.

20140187638 - Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease: The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related methods and compositions.... Agent: Gmp-orphan

20140187639 - Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof: Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward... Agent: Tufts University

20140187640 - N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce,... Agent:

20140187641 - Estrogen receptor ligands and methods of use thereof: The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing... Agent: Gtx

20140187642 - Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.... Agent: Allergan, Inc.

20140187643 - Method of treatment with anti-inflammatory and analgesic compounds which are gi-, renal-, and platelet-sparing: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.... Agent: Pathologica LLC

20140187644 - Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability: The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone,... Agent: Wockhardt Ltd

20140187645 - Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of... Agent: The Usa, As Represented By The Secretary, Department Of Health And Human Services

20140187646 - Geranylgeranylacetone formulations and retinal and systemic delivery thereof: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.... Agent:

20140187648 - Identifying subjects in need of treatment: A method of identifying a human subject, more likely than a subject selected at random from the general population, to have one or more of the following: (i) a low macular pigment concentration in the eye or eyes; (ii) a low visual performance, or (iii) an atypical “central dip” macular... Agent: Howard Foundation Holdings Ltd.

20140187647 - Methods of identifying subjects in need of treatment and methods of improving visual performance: Systems and methods may be provided for improving the visual performance of a human subject without the need to test the macular pigment concentration in the eye or eyes of the subject. The method may include identifying a subject likely to have an atypical ‘central dip’ macular pigment distribution; and... Agent: Howard Foundation Holdings Ltd.

20140187649 - Novel liquid organo polysiloxane and use therefor: The present invention relates to a liquid organopolysiloxane having fluidity at a temperature of at least 100° C., having a silicon-bonded sugar alcohol-modified group, and having a crosslinked structure comprising a carbon-silicon bond in the crosslinking portion. The liquid organopolysiloxane of the present invention has excellent emulsion characteristics, imparts excellent... Agent: Dow Coming Toray Co., Ltd

20140187650 - Method for easing human childbirth using a lubricant composition: The present invention relates to a method of easing childbirth using a composition having a lubricant effect for use in particular during human vaginal delivery. The methods comprise applying a bioadhesive composition comprising (a) a polyacrylic acid, (b) a water-soluble thickener and (c) a humectant and (d) optionally water.... Agent: Hcb Happy Child Birth Holding Ag

20140187651 - Multi-hierarchical self-assembly of a collagen mimetic peptide: The present disclosure generally relates to collagen, and more particularly compositions and methods related to collagen-mimetic peptides. More specifically, the present disclosure provides a collagen-mimetic peptide and peptide systems comprising the amino acid sequence (Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4.... Agent: William Marsh Rice University

20140187652 - L-fabp based diagnosis of kidney injury after an acute event or after a surgical intervention: Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.... Agent: Roche Diagnostics Operations, Inc.

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.45635 seconds

PATENT INFO